BioTissue Holdings, Inc
BioTissue is a leader in regenerative medicine, specializing in products derived from human amniotic membrane tissues. Since 1997, the company has pioneered the clinical application of human placental tissues, treating over 900,000 patients with its innovative products. Its mission is to empower healthcare professionals to deliver optimal healing outcomes through advanced regenerative therapies, backed by extensive research and scientific validation. The company values compassion, trust, ownership, excellence, and teamwork, aiming to set the standard for next-generation care in regenerative medicine. With over three decades of evidence-based innovation, BioTissue continues to champion high-performance healing into the future, utilizing proprietary CryoTek® technology to preserve the biological integrity of tissues.
Industries
Nr. of Employees
large (251-1000)
BioTissue Holdings, Inc
7300 Corporate Center Dr. Suite 700, Miami, FL 33126
Patents
Set for the endoscopic fixation of an implant in an intervertebral disk by means of a nail or pin
US-12329394-B2
View Details
Set for the endoscopic fixation of an implant in an intervertebral disk by means of a nail or pin
US-12329394-B2
View DetailsProducts
Cryopreserved membrane-based ocular device
A cryopreserved amniotic membrane format provided as a self-retained ocular delivery format intended to promote ocular surface healing by delivering preserved matrix and signaling molecules to the cornea.
Cryopreserved amniotic membrane grafts for ocular reconstruction
Sheet and graft formats of cryopreserved amniotic membrane for ocular surface reconstruction and surgical placement to support healing and reduce inflammation and scarring.
Cryopreserved umbilical cord tissue grafts
Thicker umbilical cord tissue allografts containing amniotic membrane components intended to provide mechanical protection, anti-inflammatory and anti-angiogenic properties for surgical applications such as implant coverage and tissue reinforcement.
Structural cryopreserved surgical allografts
Cryopreserved structural allografts for homologous surgical use as protective barriers and wound coverings in orthopedic, spine, wound care and other surgical contexts.
Cryopreserved membrane-based ocular device
A cryopreserved amniotic membrane format provided as a self-retained ocular delivery format intended to promote ocular surface healing by delivering preserved matrix and signaling molecules to the cornea.
Cryopreserved amniotic membrane grafts for ocular reconstruction
Sheet and graft formats of cryopreserved amniotic membrane for ocular surface reconstruction and surgical placement to support healing and reduce inflammation and scarring.
Cryopreserved umbilical cord tissue grafts
Thicker umbilical cord tissue allografts containing amniotic membrane components intended to provide mechanical protection, anti-inflammatory and anti-angiogenic properties for surgical applications such as implant coverage and tissue reinforcement.
Structural cryopreserved surgical allografts
Cryopreserved structural allografts for homologous surgical use as protective barriers and wound coverings in orthopedic, spine, wound care and other surgical contexts.
Services
In-person and specialty-focused educational programs for clinicians covering clinical evidence, procedural techniques and protocol implementation for regenerative tissue therapies.
Financial and educational support programs for investigator-initiated clinical studies, scientific education and fellowship programs.
Management and execution of birth-tissue donor acquisition programs, including partnerships with medical centers to ethically source amniotic membrane and umbilical cord tissues for processing.
Documentation and resource support related to regulatory registrations, quality systems, certificates of compliance and accreditation information for product use and compliance.
In-person and specialty-focused educational programs for clinicians covering clinical evidence, procedural techniques and protocol implementation for regenerative tissue therapies.
Financial and educational support programs for investigator-initiated clinical studies, scientific education and fellowship programs.
Management and execution of birth-tissue donor acquisition programs, including partnerships with medical centers to ethically source amniotic membrane and umbilical cord tissues for processing.
Documentation and resource support related to regulatory registrations, quality systems, certificates of compliance and accreditation information for product use and compliance.
Expertise Areas
- Regenerative medicine using birth tissues
- Ocular surface therapy and corneal regeneration
- Surgical allografts and structural tissue barriers
- Tissue processing and cryopreservation methods
Key Technologies
- Cryopreservation of human birth tissues preserving extracellular matrix and bioactive complexes
- HC-HA/PTX3 molecular complex identification and isolation
- Amniotic membrane and umbilical cord tissue allografts
- Tissue banking and donor acquisition systems
News & Updates
A physician summit to discuss next-generation regenerative therapies, held in California.
An educational event for urology professionals focusing on cryopreserved amniotic membrane technology.
A study demonstrating cryopreserved amniotic membrane's role in corneal nerve regeneration in dry eye disease.
Research showing cryopreservation better preserves biological properties of amniotic tissues compared to dehydration.
In 2014, BioTissue was acknowledged for its rapid growth and innovation.
A physician summit to discuss next-generation regenerative therapies, held in California.
An educational event for urology professionals focusing on cryopreserved amniotic membrane technology.
A study demonstrating cryopreserved amniotic membrane's role in corneal nerve regeneration in dry eye disease.
Research showing cryopreservation better preserves biological properties of amniotic tissues compared to dehydration.
In 2014, BioTissue was acknowledged for its rapid growth and innovation.